Even in the darkest of times, biopharmaceutical investors and executives usually express optimism in January, when thousands gather in San Francisco for the annual J.P. Morgan Healthcare Conference to discuss where the industry is headed. As the 2026 meeting begins, though, they have reason to feel hopeful. Several indicators of sector health, from stock performance to deals and financings, turned positive in the second half of 2025. The generalist investors that abandoned biotech during a lengthy downturn tiptoed back. In a series of outlook reports late last year, multiple investment banks that follow the sector predicted that the run should continue, at least in the near term.
Read the full article: 5 Questions Facing Biopharma in 2026 //
Source: https://www.biopharmadive.com/news/biotech-pharma-outook-2026-trump-rfk-china-fda/808670/